Home > Riviste > Gazzetta Medica Italiana Archivio per le Scienze Mediche > Fascicoli precedenti > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2017 April;176(4) > Gazzetta Medica Italiana Archivio per le Scienze Mediche 2017 April;176(4):149-53

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Gazzetta Medica Italiana Archivio per le Scienze Mediche 2017 April;176(4):149-53

DOI: 10.23736/S0393-3660.16.03444-6

Copyright © 2016 EDIZIONI MINERVA MEDICA

lingua: Inglese

Effects of a novel MYRLIQ®, Ginkgo Biloba, Q10 and vitamin B2 (riboflavin) based nutraceutical in patients suffering from migraine headache without aura or sporadic episodes of tension-type headache. A six-month pilot study

Leonardo SCARZELLA 1, 2

1 Piero Pietro e Giovanni Ferrero Foundation, Alba, Cuneo, Italy; 2 Unit of Neurology, Hospital of Biella, Biella, Italy


PDF


BACKGROUND: The aim of this study was to assess the tolerability and efficacy of a novel MYRLIQ®, Ginkgo Biloba, Q10, and vitamin B2 based nutraceutical product (NP) in migraine headache without aura (MHWA) and tension-type headache (TTH).
METHODS: An open-label, prospective trial was conducted. Adult subjects of both genders were assigned to two groups according to the diagnosis (IHS guideline criteria): MHWA N.=28 or TTH N.=21. Subjects were to take NP for 7 days in the event of a headache attack over a period of 6 months. The severity of pain was measured on a Visual Analogue Scale (VAS), blood was drawn to determine interleukin IL-6, IL-8 and TNF-α plasma levels, and quality of life was assessed by asking the subject to fill in the SF-36 questionnaire (simplified version) at baseline and after 7 days of treatment. Subjects were asked to report any recurrences.
RESULTS: NP reduced VAS Score on average by two-thirds in both groups (MHWA P<0.03 and TTH P<0.01). The improvement in pain was associated with an important improvement in quality of life. NP reduced all three cytokines significantly by 40-60.7%. The highest reductions were recorded for IL-8 and TNF-α (54.4-60.5%) and were consistently more pronounced in TTH subjects. The recurrence rate was 12% in MHWA subjects 10% in TTH subjects. No adverse events were reported.
CONCLUSIONS: NP, thanks to the presence of MYRLIQ®, which possesses anti-inflammatory, analgesic and anesthetic properties, should be considered an alternative therapeutic option for the two most common types of headache, namely MHWA and TTH.


KEY WORDS: Migraine disorders - Tension-type headache - Dietary supplements - Ginkgo Biloba

inizio pagina